BR112022009563A2 - Compostos de pirrolotriazina atuando como inibidor de mnk - Google Patents

Compostos de pirrolotriazina atuando como inibidor de mnk

Info

Publication number
BR112022009563A2
BR112022009563A2 BR112022009563A BR112022009563A BR112022009563A2 BR 112022009563 A2 BR112022009563 A2 BR 112022009563A2 BR 112022009563 A BR112022009563 A BR 112022009563A BR 112022009563 A BR112022009563 A BR 112022009563A BR 112022009563 A2 BR112022009563 A2 BR 112022009563A2
Authority
BR
Brazil
Prior art keywords
pyrolotriazine
compounds acting
mnk
inhibitor
compounds
Prior art date
Application number
BR112022009563A
Other languages
English (en)
Inventor
Wu Lingyun
Wei Xiawei
Yang Peng
Zhao Lele
Zhang Chen
Jiang Ning
Zheng Wei
Li Jian
Chen Shuhui
Original Assignee
Jumbo Drug Bank Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jumbo Drug Bank Co Ltd filed Critical Jumbo Drug Bank Co Ltd
Publication of BR112022009563A2 publication Critical patent/BR112022009563A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

COMPOSTOS DE PIRROLOTRIAZINA ATUANDO COMO INIBIDOR DE MNK. São descritos compostos de pirrolotriazina que atuam como um inibidor de quinase de interação de proteína quinase ativada por mitógeno (MNK), e o uso dos mesmos na preparação de um fármaco inibidor de quinase de interação de proteína quinase ativada por mitógeno. Especificamente descritos são compostos representados pela fórmula (I) ou um sal farmaceuticamente aceitável dos mesmos.
BR112022009563A 2019-11-18 2020-11-18 Compostos de pirrolotriazina atuando como inibidor de mnk BR112022009563A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201911129114 2019-11-18
CN202010329964 2020-04-24
PCT/CN2020/129603 WO2021098691A1 (zh) 2019-11-18 2020-11-18 作为mnk抑制剂的吡咯并三嗪类化合物

Publications (1)

Publication Number Publication Date
BR112022009563A2 true BR112022009563A2 (pt) 2022-08-02

Family

ID=75981354

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009563A BR112022009563A2 (pt) 2019-11-18 2020-11-18 Compostos de pirrolotriazina atuando como inibidor de mnk

Country Status (10)

Country Link
US (1) US20220281895A1 (pt)
EP (1) EP4063364A4 (pt)
JP (1) JP7311207B2 (pt)
KR (1) KR20220101686A (pt)
CN (1) CN114728966B (pt)
AU (1) AU2020387982B2 (pt)
BR (1) BR112022009563A2 (pt)
CA (1) CA3158749A1 (pt)
MX (1) MX2022005951A (pt)
WO (1) WO2021098691A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240004828A (ko) * 2021-05-08 2024-01-11 점보 드러그 뱅크 컴퍼니 리미티드 피롤로트리아진 화합물의 염 형태, 이의 결정형 및 이의 제조 방법
WO2024017229A1 (zh) * 2022-07-19 2024-01-25 成都嘉葆药银医药科技有限公司 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
US7405213B2 (en) * 2005-07-01 2008-07-29 Bristol-Myers Squibb Company Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
WO2015091156A1 (en) * 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
TWI713455B (zh) * 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
DK3285809T3 (da) 2015-04-20 2019-11-18 Effector Therapeutics Inc Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
JP6892444B2 (ja) 2015-10-29 2021-06-23 イーフェクター セラピューティクス， インコーポレイテッド Ｍｎｋ１およびｍｎｋ２のイソインドリン、アザイソインドリン、ジヒドロインデノンならびにジヒドロアザインデノン阻害薬
WO2017075412A1 (en) 2015-10-29 2017-05-04 Effector Therapeutics, Inc. Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2
WO2017087808A1 (en) 2015-11-20 2017-05-26 Effector Therapeutics, Inc. Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
WO2017117052A1 (en) * 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
CA3050599A1 (en) * 2017-01-20 2018-07-26 Bayer Pharma Aktiengesellschaft Substituted imidazopyridinpyrimidines
DK3582776T3 (da) 2017-02-14 2024-01-08 Effector Therapeutics Inc Piperidinsubstituerede mnk-hæmmere og dertil relaterede fremgangsmåder
US10780119B2 (en) * 2017-05-24 2020-09-22 Effector Therapeutics Inc. Methods and compositions for cellular immunotherapy

Also Published As

Publication number Publication date
EP4063364A1 (en) 2022-09-28
EP4063364A4 (en) 2023-12-13
US20220281895A1 (en) 2022-09-08
JP7311207B2 (ja) 2023-07-19
KR20220101686A (ko) 2022-07-19
AU2020387982A1 (en) 2022-06-30
CN114728966B (zh) 2023-08-18
WO2021098691A1 (zh) 2021-05-27
AU2020387982B2 (en) 2023-08-03
MX2022005951A (es) 2022-07-27
CA3158749A1 (en) 2021-05-27
CN114728966A (zh) 2022-07-08
JP2023502237A (ja) 2023-01-23

Similar Documents

Publication Publication Date Title
BR112021024674A2 (pt) Derivado heterocíclico de nitrogênio com cinco membros de pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112018077015A2 (pt) derivados de ácido borônico e usos terapêuticos dos mesmos
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112022008375A2 (pt) Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste
BR112017005531A2 (pt) derivados de diaril ureia como inibidores de quinase p38
BR112018008397A2 (pt) derivados de di-hidroimidazopirazinona úteis no tratamento do câncer
BR112015011760A2 (pt) composto, uso do composto, e uso de uma composição farmacêutica
BR112016015983A2 (pt) Compostos de indazol como inibidores de irak4, seus usos, e composição farmacêutica
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
DOP2012000310A (es) Morfolinopirimidinas y su uso en terapia
BR112019024785A2 (pt) composto de bifenila ou sal do mesmo, composição farmacêutica, agente antineoplásico e uso
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
BR112017000246A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112018070536A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112021023927A2 (pt) Composto, e, composição farmacêutica
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
BR112022009563A2 (pt) Compostos de pirrolotriazina atuando como inibidor de mnk
BR112021011325A2 (pt) Derivados de rapamicina
NZ757442A (en) Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
BR112018070514A2 (pt) composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição
BR112018067552A2 (pt) inibidores de cinase